ReviewFrontiers in oncology2026
Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is one of the most harmful upper gastrointestinal cancers, particularly in its advanced stages. Squamous cell carcinoma accounts for approximately 85% of all esophageal cancer cases among Chinese patients and is the main pathological type. Although first-line immunotherapy combined with chemotherapy has improved survival rates for stage IV esophageal squamous cell carcinoma (ESCC), some patients still experience suboptimal local control due to resistance to the treatment regimen. In patients with stage IV ESCC, disease progression at the primary site typically represents the main pattern of overall disease progression. Preclinical studies have clearly demonstrated a synergistic mechanism between radiotherapy and immunotherapy, and clinical evidence strongly suggests that the addition of consolidation radiotherapy can effectively enhance local lesion control and significantly prolong survival. Therefore, this review aims to explore the mechanisms of action of consolidation radiotherapy following first-line immunotherapy combined with chemotherapy in patients with stage IV ESCC, and to further analyze its feasibility and implementation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.